← Back to Search

Behavioural Intervention

Telemedicine for Movement Disorders

N/A

Recruiting

Research Sponsored by University of Vermont

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

Study Summary

This trial will evaluate if telemedicine can be used to provide similar care to people with drug-induced movement disorders instead of in-person visits.

Who is the study for?

Adults who can consent and are willing to share clinical info with a neurology team. They must be able to travel for in-person visits or have internet access for telemedicine appointments. It's not for hospitalized patients or those needing care beyond the study's scope.Check my eligibility

What is being tested?

The trial is testing if telemedicine consultations are as effective as in-person visits for treating drug-induced movement disorders. Participants will randomly receive either type of consultation, and researchers will use the RE-AIM framework to evaluate outcomes.See study design

What are the potential side effects?

Since this trial compares two types of medical consultations rather than medications, there aren't direct side effects like you'd expect from drugs; however, technical issues or limitations in remote communication could potentially affect the quality of care.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Effectiveness; Client Satisfaction Questionnaire-8 (CSQ-8)

Secondary outcome measures

Effectiveness; MHC survey and Qualitative Interviews

Effectiveness; PROMIS 29+2 V2.1

Effectiveness; referral forms and visit notes

+1 more

Other outcome measures

Adoption

Implementation

Maintenance; MHC survey and qualitative interviews

+1 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: TelemedicineExperimental Treatment1 Intervention

Group II: In-PersonExperimental Treatment1 Intervention

Control group

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Neurocrine BiosciencesIndustry Sponsor

75 Previous Clinical Trials

6,721 Total Patients Enrolled

University of VermontLead Sponsor

266 Previous Clinical Trials

3,743,661 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still recruitment opportunities for participants in this research program?

"Affirmative, clinicaltrials.gov lists this medical trial as actively recruiting. It was initially posted on April 26th 2022 and the text has been revised most recently on September 23rd 2023. The study seeks to enrol 30 persons at a single site."

Answered by AI

What is the approximate number of participants that are taking part in this experiment?

"Affirmative. The information accessible on clinicaltrials.gov alludes to this trial being actively recruiting participants, which was first advertised on April 26th 2022 with the latest alterations occurring September 23rd 2023. This study requires 30 people from one particular location for participation."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluating a Telemedicine Neurological Consult Program for Drug-Induced Movement Disorders Using the RE-AIM Framework

Emily Houston 2022. "Evaluating a Telemedicine Neurological Consult Program for Drug-Induced Movement Disorders Using the RE-AIM Framework". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06060444.